schizophrenia
EA Pharma announces phase 3 trial for new schizophrenia treatment in Japan
January 7, 2026Research and Development Psychiatry, ea pharma, schizophrenia
EA Pharma, a subsidiary of Eisai, has announced the initiation of a phase 3 clinical trial of evenamide, a schizophrenia …
Alto Neuroscience’s schizophrenia treatment granted FDA Fast Track designation
October 14, 2025Alto Neuroscience, FDA, schizophrenia
Alto Neuroscience has announced that its investigational treatment for cognitive impairment associated with schizophrenia (CIAS) has received Fast Track designation …
Johnson & Johnson submits FDA application for Caplyta to prevent schizophrenia relapse
July 18, 2025Medical Communications, Research and Development CAPLYTA, Johnson & Johnson, Neurology, US Food and Drug Administration, neuroscience, new drug application, schizophrenia
Johnson & Johnson has submitted a supplemental New Drug Application to the US Food and Drug Administration (FDA) for Caplyta …
Newron’s programme for treatment-resistant schizophrenia therapy approved
May 13, 2025Research and Development Newron, Psychiatry, clinical trials, psychiatry, schizophrenia
Newron Pharmaceuticals has announced the approval for its ENIGMA-TRS phase 3 development programme evaluating evenamide as an add-on therapy to …
Abbvie acquires Cerevel Therapeutics
August 2, 2024Mergers and Acquisitions AbbVie, Cerevel Therapeutics, Drug-Resistant Epilepsy, Neurology, Parkinson's disease, major depressive disorder, mergers & acquisitions, neurology, neuroscience, schizophrenia
Abbvie has announced the acquisition of Cerevel Therapeutics, strengthening its neuroscience pipeline. Cerevel has multiple programmes across neurological and psychiatric …
Nxera Pharma partner Neurocrine Biosciences enters phase 1 NBI-1117567 study
May 9, 2024Research and Development Alzheimer's disease, Neurocrine Biosciences, Neurology, Nxera Pharma, Parkinson's disease, clinical trials, dementia, schizophrenia
Nxera Pharma’s neuroscience-focused biopharmaceutical partner  Neurocrine Biosciences has announced it has successfully started its phase 1, first-in-human trial of investigational …
FDA accepts NDA for Karuna’s schizophrenia treatment
November 30, 2023Medical Communications FDA, Karuna Therapeutics, NDA, Neurology, schizophrenia
Karuna Therapeutics has announced that the US Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for …
Karuna Therapeutics submits NDA to FDA for schizophrenia treatment
September 29, 2023Medical Communications FDA, Karuna Therapeutics, Neurology, mental health, schizophrenia
Karuna Therapeutics has announced that it has submitted a New Drug Application (NDA) to the US Food and Drug Administration …
Sosei Heptares announces first subject dosed in phase 1 trial for schizophrenia therapy
July 3, 2023Research and Development HTL'149, Neurology, Sosei Heptares, clinical trial, schizophrenia
Sosei Heptares has announced that it has dosed its first patient in its phase 1 trial evaluating HTL0048149 (HTL’149), a …
Newron announce successful results from schizophrenia study
April 1, 2021schizophrenia
Newron, a biopharmaceutical company focused on novel therapies, have announced the initial results from two short-term exploratory studies assessing the …
EMA receives filing for Janssen’s twice-yearly schizophrenia jab
December 7, 2020Sales and Marketing EMA, Janssen, schizophrenia
The European Medicines Agency (EMA) has received Janssen’s Marketing Authorisation Extension for paliperidone palmitate six-monthly (PP6M), an injectable therapy administered …
Clinical trial suggests new schizophrenia drug could reduce symptoms
April 16, 2020Business Services D2, clinical trials, schizophrenia
Results from a newly published clinical trial suggest that a new compound could treat a broad range of schizophrenia symptoms. …
FDA approves first and only transdermal patch for schizophrenia
October 16, 2019Research and Development, Sales and Marketing FDA, Noven Pharma, Secuado, US, pharma, schizophrenia
Hisamitsu Pharmaceutical subsidiary Noven Pharmaceuticals has revealed the FDA approval of Secuado (asenapine) in adult schizophrenia patients, making it the …
Acadia’s schizophrenia drug flops in Phase 3 trial
July 23, 2019Manufacturing and Production acadia, clinical trials, menatl health, neuroscience, pharma, phase 3, schizophrenia
Acadia Pharmaceuticals has said its schizophrenia drug Nuplazid (primavanserin) has failed to beat placebo in a Phase 3 trial. Nuplazid …
FDA delays Newron Pharmaceuticals’ trial into schizophrenia drug evenamide
May 28, 2019Manufacturing and Production Newron Pharma, evenamide, pharma, schizophrenia
Newron Pharmaceuticals has halted a clinical trial of its schizophrenia drug evenamide after the FDA raised concerns about reports of …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
